The European Commission (EC) has approved a Marketing Authorization (MA) for Tremfya (guselkumab) to treat adults with ...

Johnson & Johnson (J&J) has shared positive long-term results from a phase 3 trial of its dual-acting IL-23 inhibitor Tremfya ...

Drug major Johnson & Johnson (JNJ) announced Monday positive new data from the Phase 3 ASTRO study evaluating TREMFYA (guselkumab) subcutaneous (SC) induction therapy ...

Biologics targeting interleukin (IL)-12, IL-23, and IL-17 may have valuable safety benefits among older adults with psoriatic disease, as a lower rate of serious infection was observed among these ...

New long-term extension data from the Phase IIb/III QUASAR trial demonstrate that Tremfya (guselkumab) maintains durable ...

The authors of a review article on the future of ustekinumab biosimilars for treating Crohn disease (CD) discussed key ...

A real-world study finds elderly psoriasis patients treated with IL-17 and IL-23 inhibitors achieve comparable long-term ...

Recent years have seen significant advancements in UC treatment, offering renewed hope for patients seeking effective and ...

AbbVie had a strong Q1 performance in its oncology, neuroscience, and immunology franchises. Read why I continue to rate ABBV ...

AbbVie Inc.'s Q1 earnings highlight an 8.4% revenue boost, driven by Skyrizi & Rinvoq. Click for ABBV's market expansion, rising EPS, and strong dividend yield.

Studies involving multiple aspects of plaque psoriasis evolution, persistence, and progression have produced clues and ...